DAC Meeting Outcome

DAC Meeting Outcome - Nov 2025

-
The HA Drug Advisory Committee (DAC), comprising doctors, clinical pharmacologists and pharmacists, systematically appraises new drugs every three months. DAC is supported by expert panels which provide specialist views on the selection of drugs for individual specialties.

Drug Advisory Committee November 2025 Meeting Outcome

 

Generic / Brand name

Meeting outcome

Primary reason for unsuccessful application1

1

Adalimumab (Hyrimoz)

Approved

 

2

Amivantamab (Rybrevant)

Unsuccessful

Insufficient evidence to demonstrate significant clinical outcome benefits

3

Asciminib (Scemblix)

Approved

 

4

Baloxavir (Xofluza)

Unsuccessful

Alternative(s) available in HADF with comparable benefits

5

Benralizumab (Fasenra)

Approved

 

6

Cerebrolysin (Cerebrolysin)

Approved

 

7

Daratumumab / Lenalidomide (Darzalex/Revlimid)

Unsuccessful

The justification of the treatment’s cost in relation to its benefits is insufficient

8

Denosumab (Jubbonti / Wyost)

Unsuccessful

Proposed treatment poses operational difficulties

9

Dupilumab (Dupixent)

Unsuccessful

Major budget impact 

10

Durvalumab (Imfinzi)

Approved

 

11

Efanesoctocog alfa (Altuviiio)

Approved

 

12

Eladocagene exuparvovec (Upstaza)

Pending

Pending further information

13

Epcoritamab (Epkinly)

Approved

 

14

Etanercept (Erelzi)

Approved

 

15

Etranacogene dezaparvovec (Hemgenix)

Unsuccessful

The justification of the treatment’s cost in relation to its benefits is insufficient

16

Faricimab (Vabysmo)

Approved

 

17

Glofitamab (Columvi)

Approved

 

18

Idursulphase Beta (Hunterase)

Pending

Pending further information

19

Lebrikizumab (Ebglyss)

Pending

Pending further information

20

Lorlatinib (Lorviqua)

Approved

 

21

Maribavir (Livtencity)

Unsuccessful

The justification of the treatment’s cost in relation to its benefits is insufficient

22

Momelotinib (Omjjara)

Approved

 

23

Nirsevimab (Beyfortus)

Approved

 

24

Nivolumab (Opdivo)

Approved

 

25

Quizartinib (Vanflyta)

Unsuccessful

The justification of the treatment’s cost in relation to its benefits is insufficient

26

Ribociclib (Kisqali)

Approved

 

27

Tezepelumab (Tezspire)

Approved

 

28

Ustekinumab (Wezlana)

Unsuccessful

Alternative(s) available in HADF with comparable benefits

29

Vonoprazan (Vocinti)

Approved

 

30

Vosoritide (Voxzogo)

Unsuccessful

Insufficient evidence of long-term clinical outcome benefits 
1 The evaluation embraces the principles of safety, efficacy and cost-effectiveness and takes into account other relevant factors, including international recommendations and practices, advance in technology, disease state, patient compliance, quality of life, actual experience in the use of drugs as well as views of professionals and patients groups.